Furthermore, Greiner et al., investigated the influence of nivolumab and anti-CTLA4 antibody ipilumumab on specific immune response to several LAA, namely PRAME, RHAMM, WT1, and #3 peptide from NPM1-mutated protein, by specific T cells, stimulated from 12 AML patients, including five cases harboring NPM1 mutations, against leukemic myeloid blasts and colony-forming cells including leukemic progenitor cells (CFC/LPC) [73]. Here, PRAME is linked to acute myeloid leukemia.